The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.
 
James Chih-Hsin Yang
Honoraria - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Gilead Sciences (Inst); Lilly; MSD; MSD Oncology (Inst); Novartis; Ono Pharmaceutical; Pfizer; Pfizer (Inst); Roche; Roche/Genentech (Inst); Sanofi/Regeneron (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst)
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Bayer (Inst); Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst); Yuhan
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Ludovic Doucet
No Relationships to Disclose
 
Mengzhao Wang
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Laurent Greillier
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; MSD; Pfizer; Roche
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Bruna Pellini
Employment - H. Lee Moffitt Cancer Center and Research Institute
Honoraria - AstraZeneca; Foundation Medicine; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Roche; Gilead Sciences; Illumina; Merus; Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); Bristol-Myers Squibb; Moffitt Cancer Center (Inst); National Cancer Institute (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche
 
Joaquim Bosch-Barrera
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche; Sanofi/Regeneron
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Takeda
 
Manuel Cobo
Consulting or Advisory Role - Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Lilly, MSD, Takeda, Phyzer, Kyowa, Sanofi,Jansen
Speakers' Bureau - Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Lilly, MSD, Takeda, Kyowa, Pierre-fabre, Novocure, Sanofi, Jansen
 
Alessandra Bearz
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pfizer; Regeneron; Takeda
Speakers' Bureau - Lilly; Lilly; Pfizer; Roche/Genentech
Research Funding - Janssen Oncology
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Lyudmila Bazhenova
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; Bayer; BioAtla; BMS GmbH & Co. KG; Boehringer Ingelheim; Elevation Oncology; Genentech/Roche; Gilead Sciences; InterVenn Biosciences; Janssen Oncology; Merck; neuvogen; Novocure; Pfizer; Regeneron; Sanofi; Summit pharmaceuticals; Teligene
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Genentech; Gilead Sciences; Janssen; Regeneron
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
 
Marcello Tiseo
Consulting or Advisory Role - Astrazeneca, MSD, Pfizer, Eli Lilly, Roche, BMS, Amgen, Sanofi, Merck, BI, Takeda, Novartis, Janssen, Daiichi Sankyo
Research Funding - Astrazeneca, BI (Inst)
Travel, Accommodations, Expenses - Amgen
 
Hector Soto Parra
No Relationships to Disclose
 
Li Zheng
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention